219 related articles for article (PubMed ID: 2531219)
61. A comparative study of renal scintigraphy and clearance with 99mTc-MAG3 and 123I-hippurate in patients with renal disorders.
Müller-Suur R; Bois-Svensson I; Mesko L
Contrib Nephrol; 1990; 79():32-5. PubMed ID: 2146087
[No Abstract] [Full Text] [Related]
62. 99mTc-MAG3 renography: normal values for MAG3 clearance and curve parameters, excretory parameters, and residual urine volume.
Esteves FP; Taylor A; Manatunga A; Folks RD; Krishnan M; Garcia EV
AJR Am J Roentgenol; 2006 Dec; 187(6):W610-7. PubMed ID: 17114514
[TBL] [Abstract][Full Text] [Related]
63. Quantification of renal function with a count-based gamma camera method using technetium-99m-MAG3 in children.
Itoh K; Nonomura K; Yamashita T; Kanegae K; Murakumo M; Koyanagi T; Furudate M
J Nucl Med; 1996 Jan; 37(1):71-5. PubMed ID: 8544005
[TBL] [Abstract][Full Text] [Related]
64. Optimum sample times for single-injection, multisample renal clearance methods.
Russell CD
J Nucl Med; 1993 Oct; 34(10):1761-5. PubMed ID: 8410295
[TBL] [Abstract][Full Text] [Related]
65. Clinical experience with 99mTc-MAG3, mercaptoacetyltriglycine, and a comparison with 99mTc-DTPA.
Al-Nahhas AA; Jafri RA; Britton KE; Solanki K; Bomanji J; Mather S; Carroll MA; Al-Janabi M; Frusciante V; Ajdinowic B
Eur J Nucl Med; 1988; 14(9-10):453-62. PubMed ID: 2975219
[TBL] [Abstract][Full Text] [Related]
66. Technetium-99m mercaptoacetyltriglycine clearance values in children with minimal renal disease: can a normal range be determined?
Meyer G; Piepsz A; Kolinska J; Lepej J; Sixt R; Hahn K
Eur J Nucl Med; 1998 Jul; 25(7):760-5. PubMed ID: 9662599
[TBL] [Abstract][Full Text] [Related]
67. Reproducibility of technetium-99m mercaptoacetyltriglycine clearance in patients with impaired renal function.
Erdil TY; Dede F; Tuglular S; Sen F; Ones T; Farsakoglu Z; Inanir S; Ozener C; Akoglu E; Turoglu T
Nucl Med Commun; 2006 Feb; 27(2):191-6. PubMed ID: 16404234
[TBL] [Abstract][Full Text] [Related]
68. 99mTc renal tubular function agents: current status.
Eshima D; Fritzberg AR; Taylor A
Semin Nucl Med; 1990 Jan; 20(1):28-40. PubMed ID: 2136959
[TBL] [Abstract][Full Text] [Related]
69. 99mTc-MAG3: a routine renal radiopharmaceutical.
Britton KE; Miceva S; Al-Nahhas AM; Jafri RA; Bomanji J; Solanki K; Carroll MJ; Nimmon CC
Contrib Nephrol; 1990; 79():28-31. PubMed ID: 2146086
[No Abstract] [Full Text] [Related]
70. Estimation of 99mTc-MAG3 clearance by single-sample methods and camera-based methods.
Inoue Y; Yoshikawa K; Yokoyama I; Ohtomo K
Ann Nucl Med; 2000 Oct; 14(5):329-32. PubMed ID: 11108160
[TBL] [Abstract][Full Text] [Related]
71. Reproducibility of single-sample clearance of 99mTc-mercaptoacetyltriglycine and 131I-orthoiodohippurate.
Russell CD; Dubovsky EV
J Nucl Med; 1999 Jul; 40(7):1122-4. PubMed ID: 10405130
[TBL] [Abstract][Full Text] [Related]
72. Evaluation of technetium-99m-ethylenedicysteine in renal disorders and determination of extraction ratio.
Kabasakal L; Atay S; Vural VA; Ozker K; Sönmezoglu K; Demir M; Uslu I; Işitman AT; Onsel C
J Nucl Med; 1995 Aug; 36(8):1398-403. PubMed ID: 7629584
[TBL] [Abstract][Full Text] [Related]
73. An investigation of factors that might influence the radiochemical purity and stability of 99mTc-MAG3.
Millar AM; O'Brien LM
Eur J Nucl Med; 1990; 16(8-10):615-9. PubMed ID: 2143474
[TBL] [Abstract][Full Text] [Related]
74. [Clinical evaluation of a new radiopharmaceutical agent 99mTc-mercaptoacetyltriglycine (MAG3)].
Lepej J; Altmann P; Marosová A; Horák V; Kliment J; Buchanec J; Pullmann R; Radakovic M; Holan J; Svitác J
Cesk Farm; 1990 Jun; 39(4):150-4. PubMed ID: 2144213
[TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetics of technetium-99m-MAG3 in humans.
Bubeck B; Brandau W; Weber E; Kälble T; Parekh N; Georgi P
J Nucl Med; 1990 Aug; 31(8):1285-93. PubMed ID: 2143528
[TBL] [Abstract][Full Text] [Related]
76. [Unilateral effective renal plasma flow measurement using one-compartment analysis of 99mTc-MAG3 and gamma-camera renography].
Oriuchi N; Tokunaga M; Suzuki H; Inoue T; Ohnishi Y; Inoue T; Endo K
Nihon Igaku Hoshasen Gakkai Zasshi; 1995 Sep; 55(11):757-62. PubMed ID: 8532508
[TBL] [Abstract][Full Text] [Related]
77. Measurements of 99mTc-MAG3 uptake in renal transplant recipients.
Oei HY; Surachno S; Wilmink JM; van der Schoot JB
Contrib Nephrol; 1990; 79():113-7. PubMed ID: 2146080
[No Abstract] [Full Text] [Related]
78. Reproducibility of technetium-99m mercaptoacetyltriglycine clearance.
Piepsz A; Tondeur M; Kinthaert J; Ham HR
Eur J Nucl Med; 1996 Feb; 23(2):195-8. PubMed ID: 8925855
[TBL] [Abstract][Full Text] [Related]
79. [Evaluation of 99mTc-MAG3 (mercaptoacetyltriglycine) renography for pediatric patients].
Tabuchi K; Adachi I; Doi K; Hou N; Komori T; Nakata Y; Matsui R; Sueyoshi K; Narabayashi I
Kaku Igaku; 1999 Jan; 36(1):15-22. PubMed ID: 10087761
[TBL] [Abstract][Full Text] [Related]
80. Comparison of camera-based 99mTc-MAG3 and 24-hour creatinine clearances for evaluation of kidney function.
Esteves FP; Halkar RK; Issa MM; Grant S; Taylor A
AJR Am J Roentgenol; 2006 Sep; 187(3):W316-9. PubMed ID: 16928911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
